Materiały źródłowe

• #1 Lobular Breast Carcinoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK554578/

  Invasive lobular carcinoma is the second most common histologic form of breast cancer, representing 5% to 15% of all invasive breast cancers. […] This activity educates the student about the etiology, epidemiology, clinical evaluation, and the importance of treatment of lobular carcinoma of the breast. […] Describe the role of breast-conserving therapy for invasive lobar breast cancer. […] The treatment of invasive lobular carcinomas has been a topic of debate due to the potential bilaterality and multifocality that characterize these tumors. Determining the extent of invasive lobular carcinoma is very important in deciding the treatment modality. The multidisciplinary approach to the treatment includes surgery, hormonal therapy, radiation therapy, and chemotherapy. […] Mastectomy/lumpectomy is the treatment of choice of invasive lobular carcinomas in most large series, and prophylactic contralateral mastectomy is not infrequently performed.

• #2 Invasive lobular carcinoma of the breast: the increasing importance of this special subtype | Breast Cancer Research | Full Text

  https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-020-01384-6

  Invasive lobular carcinoma (ILC) is the most common of the breast cancer special types, accounting for up to 15% of all breast cancer cases. […] Since last reviewing the lobular literature (McCart Reed et al., Breast Cancer Res 17:12, 2015), there has been a considerable increase in research output focused on this tumour type, including studies into the pathology and management of disease, a high-resolution definition of the genomic landscape of tumours as well as the evolution of several potential therapeutic avenues. […] ILCs are normally oestrogen (ER) and progesterone (PR) receptor positive, and as such patients are indicated for hormone therapy. […] A recent study of Mexican breast cancer patients compared the disease-free survival and overall survival between ILC and IBC-NST. The authors showed the overall survival in both triple-negative ILC and HER2+ ILC was significantly worse compared to their IBC-NST counterparts raising the possibility that within ILC, HER2+ status or triple-negative status identifies clinically important subtypes of ILC.

• #3 Invasive lobular carcinoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/invasive-lobular-carcinoma/diagnosis-treatment/drc-20373979

  Treatment for invasive lobular carcinoma often starts with surgery to remove the cancer. Most people with breast cancer will have other treatments after surgery, such as radiation, chemotherapy and hormone therapy. Some people may have chemotherapy or hormone therapy before surgery. These medicines can help shrink the cancer and make it easier to remove. […] Invasive lobular carcinoma treatment is very similar to the treatment for other types of breast cancer. Some things that might be different with this type of cancer include: […] Most invasive lobular carcinomas are sensitive to hormones. Breast cancers that are sensitive to hormones are likely to respond to hormone-blocking treatments. This kind of treatment is called hormone therapy or endocrine therapy. […] Most invasive lobular carcinomas don’t make extra HER2. HER2 is a protein that some healthy breast cells make. Some breast cancer cells develop changes that cause them to make a lot of extra HER2. Treatments can target the cells that are making extra HER2. Invasive lobular carcinomas are less likely to make extra HER2, so they’re less likely to respond to this treatment.

• #4 What is invasive lobular carcinoma? | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/What-is-invasive-lobular-carcinoma-8-insights-on-lobular-breast-cancer.h00-159539745.html

  A recently published comprehensive review and new research being presented at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) by breast medical oncologist Jason Mouabbi, M.D., is helping to distinguish invasive lobular carcinoma as its own subtype and define more tailored treatment approaches. […] It needs to have more attention so we can find better screening, better detection and better therapies, Mouabbi says. […] Many patients with invasive lobular carcinoma receive the standard-of-care chemotherapy, but the comprehensive review showed there isnt much clinical benefit. […] We need something different for these patients. […] There are other therapies for invasive lobular carcinoma, but theyre not widely used yet. […] Because of this, lobular breast cancer can be treated with endocrine therapy.

• #5 Invasive lobular carcinoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/invasive-lobular-carcinoma/diagnosis-treatment/drc-20373979

  Your treatment plan will depend on many factors. Your healthcare team considers the stage of the cancer and how quickly it’s growing. Your care team also considers your overall health and what you prefer. […] Hormone therapy, also called endocrine therapy, uses medicines to block certain hormones in the body. It’s a treatment for breast cancers that are sensitive to the hormones estrogen and progesterone. […] Most invasive lobular carcinomas are sensitive to hormones, so they are likely to respond to this treatment. […] Radiation therapy is often used after surgery. It can kill any cancer cells that might be left after surgery. The radiation lowers the risk of the cancer coming back. […] Chemotherapy for invasive lobular carcinoma and other types of breast cancer is often used after surgery. It can kill any cancer cells that might remain and lower the risk of the cancer coming back.

• #6 Invasive lobular carcinoma | Altru Health System

  https://www.altru.org/health-library/conditions/invasive-lobular-carcinoma

  Your treatment plan will depend on many factors. Your healthcare team considers the stage of the cancer and how quickly it’s growing. Your care team also considers your overall health and what you prefer. […] Surgery for invasive lobular carcinoma typically involves a procedure to remove the breast cancer and a procedure to remove some nearby lymph nodes. Options include: […] A lumpectomy is surgery to remove the invasive lobular carcinoma and some of the healthy tissue around it. The rest of the breast tissue isn’t removed. Other names for this surgery are breast-conserving surgery and wide local excision. Most people who have a lumpectomy also have radiation therapy. […] A mastectomy is surgery to remove all breast tissue from a breast. The most common mastectomy procedure is total mastectomy, also called simple mastectomy. This procedure removes nearly all of the breast, including the lobules, ducts, fatty tissue and some skin, including the nipple and areola.

• #6 Invasive lobular carcinoma | Altru Health System

  https://www.altru.org/health-library/conditions/invasive-lobular-carcinoma

  Treatment for invasive lobular carcinoma often starts with surgery to remove the cancer. Most people with breast cancer will have other treatments after surgery, such as radiation, chemotherapy and hormone therapy. Some people may have chemotherapy or hormone therapy before surgery. These medicines can help shrink the cancer and make it easier to remove. […] Invasive lobular carcinoma treatment is very similar to the treatment for other types of breast cancer. Some things that might be different with this type of cancer include: […] Most invasive lobular carcinomas are sensitive to hormones. Breast cancers that are sensitive to hormones are likely to respond to hormone-blocking treatments. This kind of treatment is called hormone therapy or endocrine therapy. […] Most invasive lobular carcinomas don’t make extra HER2. HER2 is a protein that some healthy breast cells make. Some breast cancer cells develop changes that cause them to make a lot of extra HER2. Treatments can target the cells that are making extra HER2. Invasive lobular carcinomas are less likely to make extra HER2, so they’re less likely to respond to this treatment.

• #7 Invasive Lobular Carcinoma: Diagnosis, Treatment, & Prognosis

  https://www.nationalbreastcancer.org/invasive-lobular-carcinoma/

  Invasive lobular carcinoma (ILC) is invasive breast cancer that begins in the lobules (milk glands) of the breast and spreads into the surrounding breast tissue. ILC can also spread to other parts of the body through the blood and lymphatic systems. “Invasive” refers to the way the cancerous cells spread to, or invade, surrounding breast tissue or other parts of the body. […] Common treatments for invasive lobular carcinoma include: […] Surgery is often used to treat invasive lobular carcinoma. There are generally two main types of breast cancer surgery for ILC: […] Radiation uses high-energy rays to destroy cancer cells and may be used after breast surgery to destroy any ILC left behind and reduce the chance of the cancer coming back. It is often used after a lumpectomy. […] Chemotherapy uses a combination of oral or intravenous (IV) drugs to destroy cancer cells or slow their growth. The use of chemotherapy depends on the prognostic factors—or features—of the breast cancer, such as hormone receptor and HER2 status.

• #8

  https://www.aurorahealthcare.org/services/cancer/breast-cancer/invasive-lobular-carcinoma

  Invasive lobular carcinoma (ILC) is a form of breast cancer that begins in the milk-producing glands of the breast. […] We offer the latest ILC treatments and diagnostic tests ranging from genetic testing to new clinical trials, ensuring you receive the most comprehensive cancer care available in Wisconsin. […] Treatment for invasive lobular carcinoma may involve a combination of surgery, radiation therapy, chemotherapy, hormone therapy and targeted therapy. […] Possible ILC treatments include: […] Surgical options for ILC include a mastectomy, which involves the partial or full removal of the breast tissue, or a lumpectomy (breast conserving surgery). […] If you have a lumpectomy, your doctor will give you radiation therapy to kill any remaining cancer cells in your breast and reduce the risk of it returning.

• #9 Invasive lobular carcinoma | Beacon Health System

  https://www.beaconhealthsystem.org/library/diseases-and-conditions/invasive-lobular-carcinoma?content_id=CON-20373955

  A lumpectomy is surgery to remove the invasive lobular carcinoma and some of the healthy tissue around it. The rest of the breast tissue isn’t removed. Other names for this surgery are breast-conserving surgery and wide local excision. Most people who have a lumpectomy also have radiation therapy. […] A mastectomy is surgery to remove all breast tissue from a breast. The most common mastectomy procedure is total mastectomy, also called simple mastectomy. This procedure removes nearly all of the breast, including the lobules, ducts, fatty tissue and some skin, including the nipple and areola. […] Hormone therapy, also called endocrine therapy, uses medicines to block certain hormones in the body. It’s a treatment for breast cancers that are sensitive to the hormones estrogen and progesterone.

• #10 Lumpectomy and radiation treatment for invasive lobular carcinoma of the breast – PubMed

  https://pubmed.ncbi.nlm.nih.gov/8942552/

  Large studies have shown a similar outcome when comparing mastectomy with lumpectomy and external beam radiation therapy in the treatment of infiltrating ductal carcinoma. However, this has not been studied extensively for invasive lobular carcinoma. […] Patients with ILC or ILC/IDC can be effectively treated with lumpectomy and radiation for stage I and II tumors while maintaining a low risk of local recurrence and equivalent overall survival.

• #11 Invasive Lobular Cancer (ILC) Melbourne, VIC | Radiotherapy Melbourne, VIC

  https://www.melbournebreastcancersurgery.com.au/breast-cancer/invasive-lobular-cancer-ilc.html

  Despite these differences, current treatment guidelines are similar for ILC and NST. […] In most cases of breast cancer, breast-conserving surgery by wide local excision is performed to remove the tumour with a margin of the surrounding normal tissue. However, in ILC, there is evidence that 17-65% of patients have to undergo a second surgical intervention. […] Consequently, patients with ILC are more likely to undergo breast removal by mastectomy. […] Neoadjuvant chemotherapy (NAC) is aimed at improving rates of breast-conserving surgery. However, consensus has emerged that ILC tends to respond poorly to chemotherapy, leading to lower disease-free and overall survival following neoadjuvant chemotherapy compared with IDC. […] Neoadjuvant chemotherapy is generally not considered for patients with early operable, ILC that is not locally advanced, as it is unlikely to improve rates of breast-conserving surgery but exposes patients to toxicities that can be life threatening.

• #12 Lobular Carcinoma

  https://www.upmc.com/locations/hospitals/magee/services/magee-womens-cancers/breast-cancer-program/types-of-breast-cancer/lobular-carcinoma

  Sentinel lymph node biopsy: A minimally invasive procedure to remove lymph node tissue in the armpit to check if existing breast cancer is spreading (metastasizing). Women diagnosed with an invasive breast cancer typically undergo a sentinel lymph node biopsy. […] Axillary lymph node dissection: Surgery to remove all or a group of lymph nodes in the underarm (axilla), if your sentinel lymph node biopsy is positive for cancer. […] Chemotherapy: The administration of drugs to destroy the growth abilities of cancer cells. It is sometimes used with radiation therapy. […] Radiation therapy: The use of beams of high-energy waves of ion particles to destroy the growth abilities of cancer cells. External radiation therapy directs rays at the tumor from outside a person’s body. […] Hormone therapy: The use of drugs that stop the production of certain hormones that the cancer needs to grow.

• #13 Treatment | Lobular Breast Cancer UK

  https://lobularbreastcancer.org.uk/treatment/

  You may be offered reconstruction after mastectomy, this is when either your own body fat will be used to make a new breast, or a synthetic implant is used. […] You may be given chemotherapy if there is cancer in your nodes, or elsewhere. Not everyone who has breast cancer is given chemotherapy. Many Lobular Breast Cancer patients do not have chemotherapy as research has shown it to not respond as well to the treatment. […] Radiotherapy might be offered to you after surgery to kill any remaining cancer cells in your breast. […] You may be given hormone therapy, but not everyone’s cancer will respond to hormones. […] You may be given targeted therapy to block the growth or spread of cancer by targeting specific molecules, at a cellular level. […] You may be offered bisphosphonates as part of your treatment. Different types of bisphosphonates are given to protect your bones from hormone treatment and/or reduce the risk of breast cancer spreading to your bones. […] There are different treatments available for secondary disease but timely diagnosis and meaningful vigilance is paramount in managing the disease.

• #14 Invasive Lobular Carcinoma (ILC)

  https://www.tripletfoundationforbreastcancer.org/post/invasive-lobular-carcinoma-ilc-4

  Treatment of invasive lobular carcinoma […] Treatments for invasive lobular carcinoma may include: […] Surgery: You and your doctor will work together to determine the type of surgery that is right for you, based on the characteristics of the cancer, your family and medical history, and your preferences. […] Radiation therapy: Radiation therapy is always recommended after lumpectomy and may be recommended after mastectomy if the cancer is large, or cancer is found in the lymph nodes. […] Chemotherapy: Chemotherapy may be given before or after surgery. Your doctor will consider the characteristics of breast cancer and your medical history when deciding if chemotherapy is right for your unique situation. […] Hormonal therapy: If breast cancer has receptors for the hormone estrogen, progesterone, or both, your doctor will recommend hormonal therapy, which is also called anti-estrogen therapy or endocrine therapy. Hormonal therapy medicines work by lowering the amount of estrogen in the body or by blocking the action of estrogen on breast cancer cells.

• #15 Lobular Breast Carcinoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK554578/

  Surgery and radiotherapy provide locoregional control. […] Adjuvant hormone therapy is also indicated, given the high percentage of cases that are positive for ER and PR. […] Chemotherapy is of limited benefit for patients with invasive lobular carcinoma, owing to the low proliferation rates observed in the vast majority of classic invasive lobular carcinoma. […] Breast-conserving surgery (wide local excision) with radiotherapy or mastectomy, depending on the site and size of the tumor and patient choice, is an adequate treatment modality for invasive lobular carcinomas as for other invasive breast cancers. […] Radiation therapy following breast-conserving surgery remains the quality of care. It not only decreases the prospect of recurrence within the breast but also improves overall survival. […] The largely estrogen receptor-positive phenotype of invasive lobular carcinoma is central to the principles of management and the observed responses.

• #16 Invasive Lobular Carcinoma (ILC)

  https://www.tripletfoundationforbreastcancer.org/post/invasive-lobular-carcinoma-ilc-4

  To decrease the chance of your cancer returning, hormone therapy can be used before or after surgery or other treatments. If the cancer has already spread, hormone therapy may shrink and control it. […] Treatments that can be used in hormone therapy include: […] Medications that block hormones from attaching to cancer cells (selective estrogen receptor modulators) […] Medications that stop the body from making estrogen after menopause (aromatase inhibitors) […] Surgery or medications to stop hormone production in the ovaries. […] Radiation therapy uses high-powered energy, such as X-rays and protons, to kill cancer cells. […] During radiation therapy, you lie on a table while a large machine moves around you, directing energy beams at precise points in your breast. […] Radiation therapy may be recommended after a lumpectomy. It may also be recommended after a mastectomy if your cancer is large or involves the lymph nodes.

• #17 Invasive Lobular Carcinoma: Symptoms, Treatment, Research | BCRF

  https://www.bcrf.org/about-breast-cancer/invasive-lobular-carcinoma/

  Lobular carcinoma is treatable but has a unique biology that affects symptoms, diagnosis, and therapeutic strategies. […] The majority of these cancers are hormone receptor (HR)positive, so endocrine (anti-hormone) therapies are typically administered for lobular breast cancer treatment. Most commonly, the anti-estrogen therapy tamoxifen is recommended for premenopausal women while an aromatase inhibitor such as letrozole or anastrozole is given to postmenopausal women. Although lobular breast cancer responds to hormone therapies, tumors can become resistant to treatment. […] Invasive lobular carcinoma has generally been treated like HR-positive invasive ductal carcinoma, but there are marked differences in how the two types of invasive carcinoma respond to hormone therapies. This may be due to the unique biology of lobular breast cancer. Recent studies profiling lobular tumors suggest that some common genetic mutations cause a poorer response to hormone therapies and drive resistance. Researchers are working to target these genes to reverse the therapeutic resistance surrounding invasive lobular carcinoma.

• #18 Invasive Lobular Carcinoma | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/breast-cancer/invasive-lobular-carcinoma.html

  Invasive lobular carcinoma treatment includes: […] Surgery: Most women diagnosed with ILC get surgery to remove the growth. Patients undergo one of the following procedures: Lumpectomy: In a lumpectomy surgery, the tumor and a small amount of surrounding healthy tissue are removed. This procedure may be used for early breast cancer cases where the tumor is still small. Lumpectomies are usually outpatient procedures and have shorter recovery times. Mastectomy: In a typical mastectomy, the entire breast with the tumor is removed. There are several different types of mastectomies, including procedures that let the patient keep the breast’s skin and nipple/areola. Often a mastectomy and breast reconstruction can be performed in the same procedure. […] Hormone therapy: Many breast cancers have high levels of hormone receptors on or in the cancer cells. When these receptors interact with hormones, they send signals to the cancer cells to rapidly grow and multiply. Hormone therapy interferes with this interaction, slowing or stopping the growth of cancer. Most ILCs have high levels of the receptor for the female hormone estrogen. Patients with these cancers receive hormone therapy, which blocks the interaction of estrogen with the cancer cells’ estrogen receptors or lowers the body’s natural estrogen production.

• #19 Invasive Lobular Carcinoma: Diagnosis, Treatment, & Prognosis

  https://www.nationalbreastcancer.org/invasive-lobular-carcinoma/

  Hormonal therapy uses drugs to block or lower the levels of hormones, such as estrogen and progesterone, in the body, which can help slow or stop the growth of some breast cancers, including invasive lobular carcinoma. […] Targeted therapy to treat invasive lobular carcinoma uses drugs that are directed (targeted) at proteins in cancerous cells, most commonly HER2 proteins, slowing down or stopping cell growth. […] When detected and treated in the early stages, the prognosis for invasive lobular carcinoma is very good. Because ILC is a slow-growing cancer, there is more opportunity to catch it in the early stages when it is easier to treat.

• #20

  https://www.advocatehealth.com/health-services/cancer-institute/cancers-we-treat/breast-cancer/invasive-lobular-carcinoma

  Hormone therapy: Hormone therapy, also known as endocrine therapy, is often used for ILC that is hormone-receptor positive, meaning the cells have receptors that bind to estrogen and progesterone that allow them to grow. Hormone therapy works by blocking the effects of estrogen or reducing estrogen levels in the body. […] Targeted therapy: Targeted therapy drugs specifically target certain molecules or pathways involved in cancer growth and progression. […] Your care team at Advocate Health Care will use a collaborative approach to provide the best treatment possible. Additionally, supportive care services such as counseling, nutrition therapy, palliative care and physical therapy may be offered to help you manage the physical and emotional challenges of cancer treatment.

• #21 FAQs – The Lobular Breast Cancer Alliance

  https://lobularbreastcancer.org/faq/

  6. As many lobular cancers are hormone receptor (ER) positive, endocrine therapies are a mainstay of treatment for this type of cancer. Aromatase inhibitors (AIs) are often prescribed to post-menopausal women, and tamoxifen to pre-menopausal women. Some premenopausal women will receive tamoxifen or an AI, in conjunction with ovarian suppression, particularly those patients with high risk of cancer recurrence. A large retrospective trial comparing letrozole to tamoxifen showed letrozole is superior for patients diagnosed with lobular versus ductal carcinoma, but this needs further validation. A current clinical trial is studying whether a specific endocrine therapy might be superior in post-menopausal women with ILC. […] 7. Chemotherapy decisions are determined by multiple factors, including clinical and pathological features such as tumor size, positive or negative lymph, tumor grade, tumor markers and molecular prognostic testing such as Mammaprint or Oncotype DX. Prognostic testing may help determine whether a particular cancer will benefit from chemotherapy, however, the utility of these tests for ILC specifically has only recently emerged. One study reported lower pathologic complete response in ILC than IDC when chemotherapy is given to patients prior to surgical treatment (neoadjuvant chemotherapy).

• #22 Invasive lobular carcinoma

  https://www.bcna.org.au/resources/podcasts/upfront-about-breast-cancer/upfront-about-breast-cancer/episode-22-invasive-lobular-carcinoma/

  Because lobular cancers are often very hormone sensitive. So strong ER and PR, oestrogen receptor and progesterone receptor. Turns out that many lobular cancers are relatively chemotherapy resistant. […] The main drugs are tamoxifen, which interferes with the way that oestrogen interacts with cells. […] The other drugs, so they’re called the aromatase inhibitors, anastrozole and letrozole and exemestane are the common ones, often referred to by their trade names of Arimidex, Femara. […] Endocrine therapies are a very important part of treatment of lobular cancer. We use, we are more likely to rely on those therapies than chemotherapy, so more of that and less chemotherapy on average. […] There was an analysis of that paper, of the patients in the paper, that suggested that the women who particularly gained, benefited from the AIs rather than tamoxifen are those with lobular cancer.

• #23 Invasive Lobular Carcinoma Comes Into Sharper Focus

  https://www.onclive.com/view/invasive-lobular-carcinoma-comes-into-sharper-focus

  Although neoadjuvant chemotherapy frequently is used for patients with substantial nodal involvement, this approach has mixed results for patients with ILC. […] By comparison, adjuvant chemotherapy showed a benefit in findings from a retrospective study of 2318 patients with hormone receptorpositive, HER2-negative ILC who received primary surgery followed by endocrine therapy with or without chemotherapy. […] The BIG 1-98 trial was the first trial indicating that there might be a higher benefit for an up-front aromatase inhibitor in patients who have lobular carcinoma, Loibl said. […] In terms of immunotherapy, the first clinical study designed for patients with ILC, the GELATO trial (NCT03147040), was terminated prematurely after failing to show sufficient benefit, Loibl noted.

• #24 Invasive Lobular Carcinoma: Causes, Symptoms, Diagnosis & Risk

  https://www.webmd.com/breast-cancer/lobular-carcinoma-invasive-and-in-situ

  Chemotherapy, or chemo, is when your doctor uses one or more medicines to kill cancer cells. You may get them before surgery to shrink a tumor or afterward to destroy any remaining cells. […] ILC cells often have receptors for the hormones estrogen and progesterone. Receptors are special proteins that help the hormones tell cells to grow and divide. Hormone therapy drugs for ILC lower the amount of estrogen in your body or keep it from telling cancer cells to grow. […] Hormone therapy can also reduce the risk of your cancer returning. Your doctor may keep you on hormone therapy for 5-10 years or even longer to protect against recurrence, says Thompson. […] You may notice side effects during or after cancer treatment. For example, chemotherapy can cause: Hair loss, Nail changes, Mouth sores, Loss of appetite, Weight changes, Nausea and vomiting, Diarrhea, More infections, Easy bruising or bleeding, Fatigue, Menstrual changes, Fertility problems, Brain fog, Heart damage, Nerve damage. […] Radiation may cause: Breast swelling, Pain, Skin changes, redness, or bruising, Fatigue, Breast tissue changes, Problems breastfeeding, Nerve damage, Pain and swelling in your arm or chest (lymphedema), Weakened ribs that fracture more easily, Fluid in your breast (seroma).

• #25 Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights

  https://www.mdpi.com/2072-6694/15/22/5491

  The decision concerning optimized endocrine therapy is determined by the menopausal status. […] The preferred agent in postmenopausal women is aromatase inhibitors (AI), the data from the two phase 3 clinical trials show that the addition of ovarian function suppression (OFS) agents to an aromatase inhibitor has more benefits in terms of disease free survival in HR-positive breast cancers. […] The decision regarding the benefit of extended endocrine therapy beyond 5 years in ILC patients who are at risk for late recurrences depends on the genetic risk. […] The Breast Cancer Index is a genetic test which, in summary, gives information about whether the patient will benefit from extended endocrine therapy for a period from five to ten years and a prognostic result, which tells about the patient’s risk of having late recurrences.

• #26 FAQs – The Lobular Breast Cancer Alliance

  https://lobularbreastcancer.org/faq/

  8. Endocrine therapy is the most commonly used targeted therapy. Additional targeted therapies may be used along with endocrine therapy and others are used when endocrine therapy is not appropriate. Some targeted therapies are used only for Stage IV or metastatic breast cancer while others can be used for earlier stage cancers. […] 9. ILC is most often an estrogen sensitive disease. Patients with ER positive ILC should consult with their care team before taking prescription or homeopathic medications or supplements that contain or mimic the hormone estrogen, including hormonal replacement therapies to relieve menopausal symptoms, supplements or other products that contain or mimic estrogen. General healthy lifestyle recommendations for breast cancer recurrence prevention also apply to patients with ILC, including a healthy diet, avoidance of weight gain (estrogen is produced in fat/adipose tissue), exercise, no alcohol consumption, and stress reduction. Exercise, in particular, has been shown to have a positive effect on long-term survival and breast cancer specific mortality.

• #27 Invasive Lobular Breast Cancer – Susan G. Komen®

  https://www.komen.org/breast-cancer/diagnosis/invasive-lobular-breast-cancer/

  Oncotype DX is a test of tumor tissue that can help determine the benefit of adding chemotherapy to treatment for some hormone receptor-positive, HER2-negative early breast cancers. It can help identify some people with hormone receptor-positive, HER2-negative ILC who may get a survival benefit from chemotherapy (in addition to hormone therapy). […] Although the exact treatment for breast cancer varies from person to person, evidence-based guidelines help make sure high-quality care is given. These guidelines are based on the latest research and agreement among experts. […] Talk with your health care team about which treatment guidelines they follow. […] After you get a recommended treatment plan from your health care team, study your treatment options. Together with your health care team, make thoughtful, informed decisions that are best for you. Each treatment has risks and benefits to consider along with your own values and lifestyle.

• #28 Invasive lobular carcinoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/invasive-lobular-carcinoma/diagnosis-treatment/drc-20373979

  Sometimes chemotherapy is given before surgery for invasive lobular carcinoma and other types of breast cancer. The chemotherapy might shrink the breast cancer so that it’s easier to remove. […] Targeted therapy uses medicines that attack specific chemicals in the cancer cells. By blocking these chemicals, targeted treatments can cause cancer cells to die. […] Most invasive lobular carcinomas don’t make extra HER2, so they are unlikely to respond to treatments that target HER2.

• #29 Invasive Lobular Carcinoma (ILC)

  https://www.tripletfoundationforbreastcancer.org/post/invasive-lobular-carcinoma-ilc-4

  Chemotherapy uses drugs to kill cancer cells. Treatment often involves receiving two or more drugs in different combinations. […] Chemotherapy may be recommended after surgery to kill any cells that may remain. […] Chemotherapy can also be used before surgery to shrink a large tumor. For women with larger tumors, chemotherapy before surgery may make it possible to choose lumpectomy over mastectomy.

• #30

  https://journals.lww.com/oncology-times/fulltext/2022/02200/questioning_chemotherapy_benefits_in_invasive.19.aspx

  The primary objective of the research study assessed whether patients with ILC that is HR-positive and HER2-negative derive a significant benefit from chemotherapy above what the anti-hormonal therapy can provide, Nahleh explained. […] The 5-year OS was significantly better for patients who received ET (91%) or CET (90%) as compared to CT (79%) or S only (80%), she said. Our research demonstrated that chemotherapy appears to have no significant added benefit to hormonal therapy in patients with ILBC, even in those tumors with a high 21 gene recurrence score. […] This suggests that the treatment for ILC should be based primarily on hormonal ET and chemotherapy may not add more benefit in terms of improving survival, she said. The implication of avoiding chemotherapy means less cost, less toxicity, and fewer disruptions at work while at the same time, enjoying a better quality of life.

• #31 Chemotherapy Benefits in Invasive Lobular Carcinoma

  https://www.rockymountaincancercenters.com/referring-providers-blog/chemotherapy-benefits-in-invasive-lobular-carcinoma

  The MINDACT clinical trial identified a subset of ILC patients who survived without the disease spreading or a recurrence of the disease at five years was comparable to high-risk ILCs and IDCs classified by MammaPrint. The 70-gene signature test identified patients with a genetic makeup that puts them at high risk of recurring cancer when treated alone with hormone therapy. This subset of patients may benefit from additional adjuvant treatment with chemotherapy. […] Additionally, lobular cancer responsiveness to chemotherapy has been shown to be equivalent to ductal cancer with similar profiles. Data has shown a connection in chemotherapy treatment and survival benefit for patients with an intermediate or high-level oncotype recurrence score. Research conducted on the responsiveness of lobular cancer to chemotherapy found a notable five-year survival outcome when chemotherapy is used for high-RS patients who have ILC.

• #32 Azthena logo with the word Azthena

  https://www.news-medical.net/news/20201001/Patients-with-invasive-lobular-carcinoma-could-benefit-from-additional-adjuvant-therapy.aspx

  Patients with invasive lobular carcinoma could benefit from additional adjuvant therapy. […] Adjuvant treatments, such as chemotherapy, radiation therapy or targeted therapies, are not usually offered to ILC patients after surgery as the disease is slow-growing and often responds well to hormone treatment alone. […] However, the 70-gene signature test (commercially known as MammaPrint) identified some ILC patients whose genetic make-up puts them at high risk of the cancer recurring if they are treated with hormone therapy alone. These patients may benefit from additional adjuvant therapy. […] In this sub-study of the MINDACT trial, we have investigated further the biology of ILC and have identified a subset of ILC patients who could potentially benefit from chemotherapy or other adjuvant treatments.

• #33 Invasive Lobular Breast Cancer Program | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/treatment/breast-oncology/programs/invasive-lobular-breast-cancer

  Invasive lobular breast cancer is usually estrogen receptor-positive and responds well to endocrine (hormone) therapy. […] Our specialized team of medical oncologists, surgical oncologists, radiologists, nuclear medicine experts, and pathologists has deep expertise in invasive lobular breast cancer. This multidisciplinary team works together and with you to create a personalized treatment plan tailored to your unique medical needs, beginning with your very first appointment. […] Treatment options include: […] Surgery: Most patients first undergo surgery to remove the tumor. […] Radiation therapy: Following surgery, treatment may involve radiation therapy to eliminate any remaining microscopic cancer cells at the site of the tumor. […] Systemic therapy: Chemotherapy may be given to kill cancer cells that may have escaped into the bloodstream or lymph system; however, not all patients with invasive lobular breast cancer benefit from chemotherapy. Invasive lobular breast cancer is usually estrogen receptor-positive, so our medical oncologists may recommend that some patients receive endocrine (hormone) therapy to reduce the amount of estrogen in the body or block its effect. CDK4/6 inhibitors such as abemaciclib and ribociclib may also be recommended.

• #34 Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights

  https://www.mdpi.com/2072-6694/15/22/5491

  An NAET combination with CDK4/6 inhibitors might find its use in early ILC, with one trial still trying to test its efficacy. […] The evidence for this comes from PALOMA-2 phase 3 trials with a Palbociclib and Fulvestrant combination showing an overall better survival benefit. […] However, the benefit of this therapy seems to apply to all HR+ breast cancers as was seen in a recent observational retrospective study which utilized a histology-based approach to segregate the metastatic ILC cases and to see if there was a differential benefit of the therapy in ILC cases in particular. […] The addition of targeted therapy to endocrine therapy had similar benefits in hormone receptor-positive cancers irrespective of the histology. […] The three CDK4/6i currently being explored in trials are Abemaciclib, Palbociclib, and Ribociclib.

• #35

  https://link.springer.com/article/10.1007/s12609-021-00412-4

  The PELOPS study is a prospective, randomized trial for early stage patients with HR-positive ILC or IDC. […] The GELATO study is a single arm, non-randomized phase II study enrolling patients with metastatic ILC. […] The ROLo study is a non-randomized, phase II study evaluating the use of the ROS1 inhibitor crizotinib in combination with the selective estrogen receptor degrader fulvestrant. […] As ILC is increasingly recognized as a unique subtype of breast cancer, clinical trials evaluating targeted treatment strategies for lobular cancers are emerging. […] Currently, a number of early-stage and metastatic trials testing small molecules that inhibit the tyrosine kinase ROS1, endocrine therapy strategies, CDK4/6 inhibition, immunotherapy with checkpoint inhibition, and inhibition of HER2 in patients with activating HER2-mutations are available for patients with ILC. […] It is critical that we increase access to and participation in clinical trials for patients with lobular cancer.

• #36 Developing Treatments for Invasive Lobular Carcinoma | Breast Cancer Trials

  https://www.breastcancertrials.org.au/treatments-invasive-lobular-carcinoma/?srsltid=AfmBOooUJbbAI082CAz6hJsr7aLW_3nAlG0d8DbUhFrkvvIfATfecwpH

  As part of a Clinical Fellowship project with Breast Cancer Trials, Dr Anna Sokolova, is examining a new treatment approach directed towards Invasive Lobular Carcinoma. […] So, in terms of treatment, patients with Invasive Lobular Carcinoma do not have a specific targeted treatment strategy that is unique to their clinical needs. So, patients with Invasive Lobular Carcinoma are treated in the same way as other breast cancer patients using standard treatment protocols that include surgery, radiotherapy, and chemotherapy. […] So, there is emerging evidence that a protein called ROS1 is an important target in Invasive Lobular breast cancer. And there are two recently established clinical trials in Europe that are assessing the efficacy of ROS1, targeted treatment in managing patients with Invasive Lobular breast cancer.

• #37

  https://link.springer.com/article/10.1007/s40487-019-00105-0

  In contrast, benefit from adjuvant letrozole at 8 years was identical between ILC and IDC. […] In the future, the treatment of ILC may be improved with better understanding and clinical application of its unique molecular profile. […] A study by Sikora et al. found that the ILC cell line model, MM134, is intrinsically resistant to tamoxifen and provided evidence that this could be reversed by inhibition of FGFR1. […] Response of ILC tumours to immune checkpoint inhibition is currently being investigated in a phase 2 clinical trial assessing the efficacy of carboplatin and atezolizumab in metastatic lobular breast cancer.

• #38 Improving Treatments for Invasive Lobular Carcinoma with Dr. Adrian Lee | Breast Cancer Research Foundation

  https://www.bcrf.org/blog/2024-podcast-dr-adrian-lee-invasive-lobular-breast-cancer/

  So a fundamental understanding of the molecular basis of the disease, the E-cadherin mutation, leads to the phenotype, the different growth, which leads to a problem with imaging. […] If we can catch it early enough and do surgery, we can cure most of those patients with surgery, radiation therapy, and standard therapy. […] Our current goal is really a focus on, as you said, the established disease and how do we treat it? […] So we have ways in the laboratory where we can identify those dependencies and then target them. […] The most exciting thing is what we study in the BCRF grant is that one of the things that happens is that when the cells dont bind to each other with this E-cadherin, now its not sticking the cells together. […] So we first showed that the loss of E-cadherin upregulates a classic growth factor pathway called IGF1 receptor, and there are drugs targeting that in clinical trials.

• #39 Invasive Lobular Carcinoma (ILC)

  https://www.tripletfoundationforbreastcancer.org/post/invasive-lobular-carcinoma-ilc-4

  Targeted therapy: Targeted cancer therapies are treatments that target specific characteristics of cancer cells, such as a protein that allows the cancer cells to grow rapidly or abnormally. Some targeted therapies are antibodies that work like the antibodies made naturally by our immune systems. These types of targeted therapies are sometimes called immune-targeted therapies. […] Immunotherapy: Immunotherapy medicines use the power of your bodys immune system to attack cancer cells. The characteristics of the cancer will determine if immunotherapy is an effective treatment option for you. […] Hormone therapy more properly termed hormone-blocking therapy is often used to treat breast cancers that are sensitive to hormones. Most invasive lobular carcinomas are hormone receptor-positive, meaning they use hormones to grow.

• #40 Invasive lobular carcinoma of the breast: the increasing importance of this special subtype | Breast Cancer Research | Full Text

  https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-020-01384-6

  Clinical trials recognising the unique molecular profile of ILC and the emergence of new therapeutic targets are very encouraging steps toward more tailored treatment strategies for ILC patients, and we await final outcome data on these studies. […] The aims of this study include determining whether aromatase inhibitor resistance or increased fulvestrant sensitivity is present within ILC with the intention of further refining optimal adjuvant endocrine-based treatment in this patient cohort. […] Recent studies have indicated a subset of ILC with increased lymphocytic infiltration may be responsive to immunotherapies. […] The clinical trial space for ILC has increased rapidly in the last 5 years, with targeted and chemotherapies being evaluated.

• #41 Invasive Lobular Carcinoma Comes Into Sharper Focus

  https://www.onclive.com/view/invasive-lobular-carcinoma-comes-into-sharper-focus

  Research groups in the United States and Europe are seeking to build the knowledge base about invasive lobular carcinoma in hopes that therapy can be tailored for patients with this diagnosis. […] Neoadjuvant chemotherapy is not effective for carcinomas classified as purely lobular and these patients should not be offered this approach routinely, according to Sibylle Loibl, MD, PhD. Upfront therapy with an aromatase inhibitor (AI) may be beneficial for patients with hormone receptorpositive ILC, Loibl said. […] Patients with ILC are candidates for the same treatment regimens as those with IDC, according to National Comprehensive Cancer Network guidelines. […] Although recommendations for treating patients with ILC often are similar to those for IDC, investigators are seeking to determine whether therapy choices should take histology into account.

• #42 Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights

  https://www.mdpi.com/2072-6694/15/22/5491

  Invasive lobular carcinoma (ILC), the second most common type of breast cancer, is a distinct entity. […] With advancements in digital techniques, clinical research targeting ILC specifically is imperative in this era of targeted therapy. […] Because most of these tumors exhibit estrogen receptor positivity and Her2 neu negativity, endocrine therapy has predominated to treat these tumors. However novel treatments like CDK4/6 inhibitors have shown importance and antibody drug conjugates may be instrumental considering newer categories of Her 2 Low breast tumors. […] In this narrative review, we explore multiple pathological aspects and translational features of this unique entity. […] Endocrine therapy is the widely preferred therapeutic modality for hormone receptor-positive ILC. […] Early-stage ILC has shown to have a favorable response to neoadjuvant endocrine therapy (NAET), showing volume reduction in the tumor within a few months of therapy. Aromatase inhibitors take the lead over tamoxifen for ILC treatment, as seen in two phase 3 trials, Breast International Group (BIG) 1–98 trial and ABCSG-8 study, showing overall improved survival rates with aromatase inhibitors.

• #43 Case: Invasive Lobular Carcinoma – Radiology | UCLA Health

  https://www.uclahealth.org/departments/radiology/education/breast-imaging-teaching-resources/cases/case-invasive-lobular-carcinoma

  Surgical excision with clear margins, often-times a mastectomy, is pursued in patients with ILC due to the propensity for this type of cancer to be multicentric within the breast. […] In patients with early-stage cancer, breast-conserving surgery in combination with post-operative radiation is an alternative. […] Other treatment options in early stage ILC is targeted hormone therapy since ILC is ER positive, and endocrine therapy such as aromatase inhibitors, specifically in post-menopausal women, to stop the conversion of androgens to estrogen. […] ILC has been shown to be less responsive to chemotherapy. […] In the setting of metastatic ILC, endocrine therapy has been shown to be the most crucial to management.

• #44 Metastatic Lobular Breast Cancer – Metastatic Breast Cancer AllianceScroll to top

  https://www.mbcalliance.org/projects/here-all-year/metastatic-lobular-breast-cancer/

  Invasive lobular carcinoma (ILC) is a distinct subtype of breast cancer with unique cellular structures, biology, and behavior. ILC is the 2nd most common type of breast cancer and accounts for up to 15% of all breast cancers including mixed ductal/lobular. 90% of lobular breast cancers are ER/PR+ HER2-, although there are subpopulations that are ER/PR negative, triple negative, or HER2+. This histology can also change over time due to treatment resistance and acquired genomic mutations. In addition to the most common type of Classic ILC, there are special morphological subtypes including Pleomorphic, Solid, Alveolar, and Tubulo-lobular which have different characteristics. […] Currently treatment is the same for ILC as IDC, depending on histological subtype. In early stage ILC, studies have shown some evidence that ILC may respond differently than IDC to Tamoxifen and Chemotherapy. Two recent reviews on metastatic breast cancer have shown that CDK4/6 inhibitors and Erubulin (a single agent chemotherapy) show similar efficacy in metastatic ILC when compared to IDC.

• #45 What is invasive lobular carcinoma? | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/What-is-invasive-lobular-carcinoma-8-insights-on-lobular-breast-cancer.h00-159539745.html

  Mouabbi hopes to open clinical trials at MD Anderson soon to investigate treating these cancers with immunotherapy. […] Its exciting because weve identified targets that may lead to more effective treatment, Mouabbi says. […] The retrospective analysis being presented by Mouabbi at the 2022 ASCO Annual Meeting reveals targeted therapy outcomes in patients with lobular breast cancer. We found that patients benefit from a combination of targeted therapy and endocrine therapy, Mouabbi says. […] To define more personalized approaches, Mouabbi says its critical to conduct clinical trials specific to lobular breast cancer.

• #46 69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

  https://www.cancernetwork.com/view/69-the-importance-of-tri-modality-therapy-for-de-novo-stage-iv-invasive-lobular-carcinoma-ilc-presenting-with-bone-only-metastases

  Locoregional therapy (LRT) of the primary breast carcinoma (BC) in the setting of de novo oligometastatic stage IV disease is strongly debated, despite both retrospective data and prospective trials supporting it. This study aims to determine the overall survival (OS) benefit of LRT combined with systemic therapy (ST) vs ST only in the management of invasive lobular carcinoma (ILC) presenting with de novo stage IV bone-only metastases. […] Patients with ILC and de novo bone-only metastases have a worse prognosis compared to those with IDC, but those who have LRT plus ST have a better OS than those who receive ST only. While there may be selection biases in our multi-institutional retrospective cohort, patients with ILC should be considered for LRT for the primary tumor combined with ST.

• #47 ILC Clinical Trials – The Lobular Breast Cancer Alliance

  https://lobularbreastcancer.org/ilc-clinical-trials/

  Since lobular breast cancer is a separate breast cancer histologic subtype, there is a critical need for people with ILC to participate in clinical trial research. […] Increased research could help improve detection, treatment, prevention of metastasis, and ultimately, develop a cure for people with ILC. […] Participation in clinical trials is one way that patients who are affected by ILC can help advance the understanding of lobular breast disease. […] It is also important to be aware of clinical trials that are being developed that focus exclusively on patients with ILC. […] LBCA is advocating for more clinical trials that are designed for people with ILC to both foster development of new therapies and to refine the application of current therapies specifically for ILC. […] Clinical trials help scientists and doctors to better understand how to refine current standard of care breast cancer treatments.

• #48 Reporting on invasive lobular breast cancer in clinical trials: a systematic review | npj Breast Cancer

  https://www.nature.com/articles/s41523-024-00627-5

  Invasive lobular breast cancer (ILC) differs from invasive breast cancer of no special type in many ways. Evidence on treatment efficacy for ILC is, however, lacking. […] In current clinical practice, implications of ILC histology on treatment choices are limited. Evidence on the efficacy of novel BC treatments in patients with ILC is often missing. […] The use of (neo-)adjuvant chemotherapy regimens is believed to be less beneficial in patients with ILC compared to patients with IBC-NST, even when correcting for surrogate intrinsic subtypes. […] Data from the BIG 1-98 trial suggested improved outcomes for the adjuvant use of aromatase inhibitors (AI) over tamoxifen only in patients with ILC. […] The landscape of BC treatment has broadened with the development of CDK4/6 inhibitors, oral selective estrogen receptor degrader (SERDs), immune checkpoint inhibitors (ICI), antibody-drug conjugates (ADCs) and other novel drug classes. While pure (i.e. not mixed with IBC-NST) lobular histology is found in approximately 15% of all BC, the efficacy of these novel drugs for patients with ILC is currently understudied.

• #49

  https://link.springer.com/article/10.1007/s12609-021-00412-4

  However, the appreciation for heterogeneity in breast cancer has allowed for tailoring treatment driven by tumor biology. […] There are currently active clinical trials specifically for patients with ILC or E-cadherin-deficient tumors like ILC, and others that include HR-positive tumors with a goal to enrich for patients with lobular histology. […] The ROSALINE study is designed to test ROS1 inhibition in combination with endocrine therapy in the early stage setting. […] Randomized trials have shown that the use of adjuvant endocrine therapy in the treatment of early-stage HR-positive breast cancer significantly improves disease free and overall survival. […] The differential benefit of aromatase inhibitors over tamoxifen appears relatively larger in patients with ILC compared to those with invasive ductal carcinoma.

• #50 Invasive Lobular Breast Cancer Clinical Trials and Research | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/treatment/breast-oncology/programs/invasive-lobular-breast-cancer/clinical-trials-research

  The Invasive Lobular Breast Cancer Program at Dana-Farber Brigham Cancer Center is one of the only programs in the country focusing on in-depth research for this under-studied type of breast cancer. Our multidisciplinary team of physician-scientists is leading clinical and basic science research to enhance our understanding of invasive lobular breast cancer, develop more effective diagnostic and treatment options for patients, and improve the current survival rate for patients. […] The findings suggest that patients with estrogen receptor-positive invasive lobular breast cancer might benefit from specific hormone-blocking treatments. […] Metzger also presented new research at the ESMO Breast Cancer Annual Congress in 2024: A retrospective analysis of the large clinical trials SOFT and TEXT investigating adjuvant endocrine treatment regimens in pre-menopausal women showed that exemestane (an aromatase inhibitor) with ovarian suppression was more beneficial than tamoxifen alone for invasive lobular breast cancer compared to invasive ductal breast cancer.

• #51 New Treatments for Invasive Lobular Carcinoma | Breast Cancer Trials

  https://www.breastcancertrials.org.au/developing-new-treatments-for-invasive-lobular-carcinoma/?srsltid=AfmBOor9VZFcD467kOcQsXOtEajc2Oack7Rxov4sV3PvewTJhZ_DWuvK

  As part of Breast Cancer Trials Clinical Fellowship program, Dr Anna Sokolova is investigating the expression of the ROS1 protein being an important target in invasive lobular carcinoma tumors. […] So, in terms of treatment, patients with invasive lobular breast cancer do not have a specific targeted treatment strategy that is unique to their clinical needs. So, patients with invasive lobular breast cancer are treated in the same way as other breast cancer patients using standard treatment protocols that include surgery, radiotherapy, and chemotherapy. […] So, there is emerging evidence that a protein called ROS1 is an important target in invasive lobular breast cancer. And there are two recently established clinical trials in Europe that are assessing the efficacy of ROS1 targeted treatment in managing patients with invasive lobular breast cancer.

• #52 FAQs – The Lobular Breast Cancer Alliance

  https://lobularbreastcancer.org/faq/

  1. An individuals treatment plan for ILC depends on many factors, including the size and grade of the cancer, genetic factors, lymph node involvement, and the patients overall health and individual preferences. At present, there are no ILC-specific treatment guidelines. The standard of care for early-stage treatment of hormone receptor positive ILC is to the same as treatment of hormone receptor positive IDC/NST. Recommended treatment will likely include surgery (lumpectomy or mastectomy), radiation, and systemic therapies such as chemotherapy or hormonal therapy. […] […] 2. Surgical planning takes into account how best to remove all of the cancer (i.e., achieving clear margins around the tissue removed). If the size of the tumor is too large to remove without leaving sufficient cancer free margins, or sufficient normal breast tissue, then a mastectomy may be recommended. Oncoplastic lumpectomy, a special technique that removes more tissue, has also been studied as an option to clear the margins more effectively in ILC. Initial breast conserving therapy may require additional surgery if margins are positive, to remove further cancer tissue. This is particularly true for lobular cancer, which more often presents with diffuse disease and multifocal lesions (several areas of cancer involvement within the breast) that may be difficult to detect with pre-operative imaging and during surgery. Long-term data suggests that choice of surgery (lumpectomy vs. mastectomy) does not affect long term survival.

• #53 Reporting on invasive lobular breast cancer in clinical trials: a systematic review | npj Breast Cancer

  https://www.nature.com/articles/s41523-024-00627-5

  One hypothesis to explain lower enrollment of patients with ILC is that the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) is not accurately reflecting the metastatic spread and disease progression of ILC. […] The greater likelihood of non-measurable disease in patients with metastatic ILC might thus lead to decreased enrollment in clinical drug trials for stage IV BC. […] This systematic review demonstrates that ILC is largely disregarded in many clinical trials since only 13 out of 93 manuscripts (14.0%) reported how many patients with ILC were included. […] Specific sub-analyses for ILC on prospective data to evaluate the efficacy of novel BC treatments are seldom performed. […] It is critical that patients with ILC are considered by clinical investigators and pharmaceutical industries.

• #54 Developing Treatment for Invasive Lobular Carcinoma

  https://www.onclive.com/view/developing-treatment-for-invasive-lobular-carcinoma

  Patients with ILC are usually treated the same as patients with invasive ductal carcinoma (IDC), says Oesterreich. […] Recent data have indicated mechanisms in ILC that differ from IDC, and Oesterreich says that the next step with this information is to identify pathways that are uniquely targetable in ILC. […] Sequencing and genetic profiling these tumors may identify pathways and provide the opportunity to target them, Oesterreich adds.

• #55 Seeking a Unique Treatment for Lobular Breast Cancer

  https://news.cuanschutz.edu/cancer-center/treatment-for-lobular-breast-cancer

  Though the two main histological types of breast cancer lobular and ductal are treated with the same hormonal therapies, women with lobular breast cancer often have recurrence or metastasis of the disease several years after their initial treatment. […] Based on his initial research, Sikora is now looking at what other proteins work with MDC1 to promote tumor growth and novel ways to stop that growth from happening. […] Ultimately, he hopes the research will lead to better treatment for lobular cancer patients treatment that reduces the risk of metastases and recurrences years down the road. […] For a patient with lobular cancer, ideally we could identify, using gene-expression signatures, whether this estrogen receptor-MDC1 partnership is active in the tumor. Then we can treat them accordingly. Thats the long-term goal.

• #56 Invasive Lobular Carcinoma: Symptoms, Treatment, Research | BCRF

  https://www.bcrf.org/about-breast-cancer/invasive-lobular-carcinoma/

  The lack of clinical trials specific to lobular breast cancer continues to be a major barrier to advancing treatments for patients with this disease. Though invasive lobular carcinoma is not uncommon, it represents a smaller percentage of total invasive breast cancer cases and thus these patients are underrepresented in clinical trials. Researchers are striving to increase participation of patients with lobular breast cancer in clinical trials as well as designing clinical trials specifically focused on this subtypeachieving these goals is critical to advancing our understanding of lobular breast cancer and moving treatments and disease management forward.

• #57 ILC Clinical Trials – The Lobular Breast Cancer Alliance

  https://lobularbreastcancer.org/ilc-clinical-trials/

  People with ILC participating in clinical trials may also receive a new treatment that is hoped to be more effective but not yet available outside of a research setting. […] When considering participation in a clinical trial, there are questions you might wish to explore to more fully understand what impact participation in a clinical trial will have on your life. […] Trials and studies that focus on or specifically include patients with ILC are highlighted below. […] ClinicalTrials.gov is the US governments listing of clinical trials. It includes a searchable database of clinical trials from around the world. […] See below for information on ILC-focused clinical trials and clinical trials that are to be enriched with individuals with ILC to enable analysis of the impact on lobular breast cancer.

Zobacz więcej